LEAVE NOTHING BEHIND
Minimally Invasive Micro Sclerostomy (MIMS®) is a Stent-less, Simple and Innovative procedure for Glaucoma treatment, designed to effectively lower the IOP.
MIMS® Story
Dr Douglas Argyll Robertson5 (1837-1909) was a Scottish Ophthalmologist and surgeon. Dr roberston was the first to publish a description including post-op results following the use of a trephine in the surgical treatment of glaucoma in late 19th century.This would create a small hole in the sclera (anterior sclerotomy) that would drain aqueous homor to lower IOP.
At the turn of the 20th Century, Dr Robert Henry Elliot6 (1865 – 1936) whom was a British ophthalmic surgeon and also an expert on snake venom published his work on Sclero-corneal trephining in the operative treatment of glaucoma
Read More
A Minimally invasive & Stent-less Treatment Glaucoma Innovation
At the forefront of Interventional Glaucoma treatment, MIMS® creates a direct pathway from the anterior chamber to the sub-conjunctival space during the surgery, without implanting a stent.
How MIMS® Works
It works by inserting a specially designed cutting tool into the sclera & removing a small channel of tissue. This channel will remain open & continuously drained, designed to effectively lower the IOP.
A Ready-to-Use Surgical System
MIMS® is a lightweight surgical system intended for use by trained professional ophthalmologists. It’s intuitive to operate and requires fewer staff to assist in non-surgical environments. A central control touchscreen demonstrates the surgical parameters & a foot pedal initiates the precise handheld cutting tool movement.
Precision Glaucoma Treatment Technology
Novel Glaucoma treatment practiced globally. Learn more about MIMS® surgical device innovation.
Proven Clinical Performance
85%
Medication reduction from baseline after 1 year1
38%
IOP reduction from baseline after 1 and 3 years1-4
73%
Medication reduction from baseline after 3 years2-4
MIMS® Testimonials
Prof. Dr. med. Dr. h.c. Anselm G.M. JUNEMANN, F.E.B.O.7
MIMS® is a promising minimally invasive filtering surgical procedure. It is an implant-free filtering surgery ab interno. MIMS® requires the application of MMC. As with any filtering procedure, MIMS® requires preoperative and postoperative management.
Dr. Davinder S. GROVER, MD, MPH8
MIMS® is a promising technology and technique that is minimally invasive, involves no implant, requires the use of MMC, and forms a bleb. The initial results are encouraging, and the FDA investigational process is underway. The procedure is currently being used and marketed in Europe and Israel. Real-world experience and published data will illuminate the path forward for MIMS®.
Additionally, as with all procedures, as more surgeons from around the world adopt MIMS®, the technique itself, pre- and postop- erative management, and methods of MMC application will continue to evolve and improve.
Prof. Dr. Lilit VOSKANYAN2,3
Minimally invasive anti-glaucoma surgical procedure performed with the new MIMS® surgical device was found satisfactory in open angle glaucoma patients after 3 years. The efficacy and safety (0% serious adverse events) results were found similar to other filtration procedures. However, the MIMS® procedure is simpler and faster han most other filtering procedures.
Dr. Ike AHMED
Having operated on a dozen patients with the MIMS® device and procedure, I can state that the device requires a very short learning curve, it is safe and it provides an alternative to the stent procedures. MIMS® can be easily used together with cataract surgery and it fits most glaucoma patients. The clinical data from Europe demonstrates efficacy similar to Trabeculectomy with less side effects. 97% of the patients do not require anti Glaucoma medication. The fact that nothing is left behind keeps future therapeutic options open which is a major advantage.
Prof. Dr. Noa GEFFEN4
MIMS® is a stent-less procedure. It is safer and less invasive than traditional incisional surgery. It is quick and simple to master and it can be easily combined with cataract surgery
News & Publications
October 2023
“Stent-less Glaucoma Surgery, Expanded indications sought for minimally invasive technology.9“
September 2022
“Minimally Invasive Micro Sclerostomy – Reviewing the surgical steps and outcomes for a new filtration procedure.8”
August, 2022
“MIMS® – Minimally Invasive Micro-sclerostomy: A new filtering surgical procedure.7“
References
1. Voskanyan L., Ahmed I.I.K., Gershoni A. et al., «Minimally invasive micro sclerostomy (MIMS) procedure in the treatment of open-angle glaucoma». BMC Ophthalmol 24, 122 (2024).
2. Voskanyan L. et al., « Long Term Results Of Minimally Invasive Micro Sclerostomy (MIMS®)»,10th World Glaucoma Congress, June 30, 2023, Rome Italy.
3. Voskanyan L., «Long-term results of Minimally Invasive Micro Sclerostomy (MIMS®)», Poster presented at the 41st Congress of the ESCRS, September 9, 2023, Vienna, Austria.
4. Geffen N., «Ab interno sclerostomy», Glaucoma Surgery: New Techniques on the Horizon,presented at the 10th Congress of the WGC Congress, June 30, 2023 Rome, Italy
5. Robertson D.A., «Trephining the sclerotic: a new operation for glaucoma.», Royal London Ophthalmic Hospital Reports, (Volume 8), 1876.
6. Elliot, R.H., «Sclero-corneal trephining in the operative treatment of glaucoma», 186 Pages, 2nd ed. London: George Pulman & Sons,1914.
7. Junemann A.G.M. and Redfak R., «MIMS – minimally invasive micro-sclerostomy: A new filtering surgical procedure.» Concept Ophtalmology, August 2022.
8. Grover D.S, MD, MPH, «MINIMALLY INVASIVE MICRO SCLEROSTOMY – Reviewing the surgical steps and outcomes for a new filtration procedure.», GLAUCOMA TODAY, 2022.
9. Larkin H., «Stent-less Glaucoma Surgery, Expanded indications sought for minimally invasive technology.», EUROTIME, 2023.
10. «MIMS®: WHERE NOTHING GETS LEFT BEHIND, Introducing a stentless, simple, and rapid glaucoma treatment that effectively lowers IOP without invasive surgery», The Ophtalmologist, 2022.
11. Voskanyan L., “New arrival – a fresh approach to treating glaucoma.” Presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.
12. Paper presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.